Research Topics
| J J KavanaghSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group StudyJ J Kavanagh
Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Int J Gynecol Cancer 18:460-4. 2008..Karenitecin is a well-tolerated topoisomerase compound but has minimal activity in extensively pretreated ovarian cancer with the dose-schedule employed...- Docetaxel for patients with paclitaxel-resistant Müllerian carcinomaC F Verschraegen
Departments of Internal Medicine Specialties and Biomathematics, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
J Clin Oncol 18:2733-9. 2000..To determine the efficacy and toxicity of docetaxel in patients with müllerian carcinoma resistant to paclitaxel... - What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?X Cheng
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Chemother 21:566-72. 2009..Seventeen (26.6%) patients had improved performance status scores. Bevacizumab combined with chemotherapy showed promising clinical benefits, with significant response of serum CA125 concentration and moderate adverse effects... - Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunctionN Sirisabya
Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 1439, USA
Int J Gynecol Cancer 18:648-51. 2008..These findings were similar to those for gynecological cancer patients with normal renal function. In conclusion, 20 mg/day of tamoxifen is safe and effective in gynecological cancer patients with CKD... - Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervixC F Verschraegen
Multidisciplinary Center of Gynecology Oncology, Section of Gynecologic and Medical Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer 92:2327-33. 2001..The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma... - Ovarian endometriosis associated with carcinoma and sarcoma: case reportM C Boruban
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 1439, USA
Eur J Gynaecol Oncol 29:393-6. 2008..She was again treated with doxorubicin and ifosfamide. The optimal treatment for endometriosis-associated ovarian cancer depends on the type of malignancy; simultaneously occurring multiple tumor types should be treated individually... - Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancerJ J Kavanagh
The M.D. Anderson Cancer Center, University of Texas, Houston, Texas, USA
Int J Gynecol Cancer 15:593-600. 2005..TLK286 was well tolerated in this population. TLK286 is an active agent in chemotherapy-resistant ovarian cancer. Further studies of TLK286 in platinum and paclitaxel refractory or resistant ovarian cancer are in progress... - Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistanceH T See
Department of Gynecologic Medical Oncology, Anderson Cancer Center, Houston, Texas, USA
Int J Gynecol Cancer 15:209-16. 2005..2 months (95% CI 20.1-26.4). Patients who have been deemed platinum resistant may still benefit from platinum re-treatment after an interval of treatment with nonplatinum agents... - Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapyE-J Lee
Department of Gynecologic Medical Oncology, The Univerisity of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Int J Gynecol Cancer 16:295-9. 2006.... - Clinical application of oxaliplatin in epithelial ovarian cancerS Fu
Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77230 1439, USA
Int J Gynecol Cancer 16:1717-32. 2006..This article reviews the current status of the clinical application of oxaliplatin alone and in a combination regimen in epithelial ovarian cancer treatment... - Aromatase inhibitors in ovarian cancer: is there a role?Y F Li
Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA
Int J Gynecol Cancer 18:600-14. 2008.... - Hormonal therapy in ovarian cancerH Zheng
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
Int J Gynecol Cancer 17:325-38. 2007..Molecular markers that can reliably predict major clinical outcomes should be investigated further in well-designed trials... - Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patientsS Tangjitgamol
Department of Gynecologic Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
Int J Gynecol Cancer 14:804-14. 2004..The decision to utilize third-line chemotherapy will be a balance of the limited efficacy, toxicity of the agents, and the expertise of the clinician... - Topoisomerase-I inhibitors in gynaecologic tumoursC F Verschraegen
Section of Gynecologic Medical Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
Ann Acad Med Singapore 27:683-7. 1998..Main toxic effects are haematologic and gastrointestinal. The latter remains problematic. Radiotherapy, alkylate, platinum analogs and topoisomerase II inhibitors are currently being studied in combination with camptothecins... - Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovaryA Jaishuen
Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 1439, USA
Int J Gynecol Cancer 18:379-83. 2008..This effect was confirmed by a significant improvement in her symptoms and signs, after treatment was discontinued... - Systemic anticancer therapy in gynecological cancer patients with renal dysfunctionY F Li
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
Int J Gynecol Cancer 17:739-63. 2007..We also review the formulae commonly used to estimate creatinine clearance, including Cockcroft-Gault, Chatelut, Jelliffe, Wright, and the Modification of Diet in Renal Disease study formulae... - Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years laterC F Verschraegen
Department of Gynecology Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Int J Gynecol Cancer 11:359-64. 2001..Surgical techniques do not seem to alter the prognosis. Because vulvar melanoma carries a poor prognosis at early stages, the use of adjuvant therapies needs to be studied prospectively in women affected with this disease... - Response of recurrent uterine high-grade malignant mixed müllerian tumor to letrozoleX Wang
Department of Gynecologic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Int J Gynecol Cancer 15:1243-8. 2005..Further study of letrozole for high-grade uterine MMMT is warranted... - Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic S Tangjitgamol
Department of Gynecologic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Int J Gynecol Cancer 15:646-56. 2005..03). There was a trend toward worse survival in patients with EGFR expression, but this finding was not significant. The combination of negative HER-2/neu expression and positive EGFR expression had the worst impact on survival... - Immunobiology of gestational trophoblastic diseasesX Wang
Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
Int J Gynecol Cancer 16:1500-15. 2006.... 
Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapyX Cheng
Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Gynecol Oncol 121:323-7. 2011..Endometrial stromal sarcoma (ESS) is a rare uterine malignancy. The current treatment approaches yield unsatisfactory results, and potential therapeutic targets need exploration...- Benign multicystic peritoneal mesothelioma: cases reports in the family with diverticulosis and literature reviewS Tangjitgamol
Department of Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Int J Gynecol Cancer 15:1101-7. 2005..The cysts in both cases regressed partially but the patients were relieved of their clinical symptoms, for 2 years after cystic drainage in one case and for 5 years after hormonal treatment in the other... - Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature reviewS Tangjitgamol
Department of Gynecologic Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
Int J Gynecol Cancer 14:399-422. 2004.... - Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II studyM E Gordinier
Women's Oncology, Providence, Rhode Island, USA
Int J Gynecol Cancer 12:710-4. 2002..This study indicates that first-line treatment with thiotepa and cisplatin produces significant long-term responses when tumors are sensitive. Such treatment is a reasonable option when paclitaxel is not available... - Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell linesWei Hu
Department of Gynecologic Medical Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Int J Gynecol Cancer 12:202-7. 2002..Combining these two biologic modifiers for the treatment of ovarian cancer may lower the effective dose of the retinoids, thus decreasing their side effects... - Targeted therapy for epithelial ovarian cancer: current status and future prospectsH T See
Department of Gynecological Medical Oncology and Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA
Int J Gynecol Cancer 13:701-34. 2003..In the long run, this should facilitate individualization of more effective, less toxic therapy for women with ovarian cancer... - Venous thromboembolism syndrome in gynecological cancerX Wang
Department of Obstetrics and Gynecology, Renji Hospital, Shanghai Second Medical University, Shanghai, China
Int J Gynecol Cancer 16:458-71. 2006..In summary, the interaction between the coagulation system and cancer progression is a novel promising area to be explored in the study of VTE in patients with gynecological cancer...